DYT1 dystonia is an autosomal dominant movement disorder, characterized by early onset of involuntary sustained muscle contractions. It is caused by a 3-bp deletion in the DYT1 gene, which results in the deletion of a single glutamate residue in the C-terminus of the protein TA (torsinA). TA is a member of the AAA+ (ATPase associated with various cellular activities) family of chaperones with multiple functions in the cell. There is no evidence of neurodegeneration in DYT1 dystonia, which suggests that mutant TA leads to functional neuronal abnormalities, leading to dystonic movements. In recent years, different functional roles have been attributed to TA, including being a component of the cytoskeleton and the NE (nuclear envelope), and involvement in the secretory pathway and SV (synaptic vesicle) machinery. The aim of the present review is to summarize these findings and the different models proposed, which have contributed to our current understanding of the function of TA, and also to discuss the evidence implicating TA in SV function.
Introduction
The dystonias are a clinically and genetically heterogeneous group of movement disorders characterized by the presence of involuntary sustained muscle contractions that can lead to abnormal postures, twisting movements or sometimes tremor [1] . Most of the cases are primary, in that there is no underlying cause or neuropathology, and are believed to be due to neurochemical abnormalities affecting motor control pathways. They are frequently inherited as monogenic traits [2] . One of the more common forms is DYT1 dystonia, caused by a mutation in the DYT1 gene that leads to the loss of a glutamate residue near the C-terminus of the encoded protein, TA (torsinA). TA is an AAA+ (ATPase associated with various cellular activities) protein of uncertain function, but recent studies have implicated it in a number of cellular compartments and processes, including the cytoskeleton and NE (nuclear envelope), the secretory pathway and the SV (synaptic vesicle) machinery. The present review provides an overview of previous studies on TA with a focus on those analysing synaptic dysfunction.
The genetic dystonias
The various genetic forms of dystonia are listed in Table 1 . It is pertinent to consider a number of these for clues to pathogenesis of dystonic movements. Dystonia-plus syndromes are monogenic dystonias without detectable neuroanatomical abnormalities but with additional neurological manifestations such as myoclonus and parkinsonism [2] . Dopa-responsive dystonia (DYT5) often presents as generalized dystonia with additional features of parkinsonism, and is characterized by diurnal variation of symptoms, which worsen as the day progresses. Importantly, the symptoms show a marked responsiveness to low doses of L-dopa. Most of the cases are caused by mutations in the GCH1 gene that codes for GTP-cyclohydrolase 1 [2] . This is the enzyme catalysing the first and rate-limiting step in the synthesis of tetrahydrobiopterin, an essential cofactor for the production of DA (dopamine) and the clinical phenotype is the direct result of insufficient synthesis of L-dopa and DA.
A very rare form of dystonia-plus syndrome is rapid-onset dystonia parkinsonism (DYT12), which is characterized by abrupt onset of dystonia and parkinsonism. Mutations were identified in the ATP1A3 gene that encodes the Na + /K + -ATPase subunit α3, which is exclusively expressed in neurons, and haploinsufficiency leads to reduced membrane ion transport [2] .
DYT1 dystonia
The commonest cause of early-onset primary torsion dystonia is mutation of the DYT1 gene, which is inherited as an autosomal dominant trait with reduced penetrance, suggesting that there may be additional genetic and/or environmental factors that trigger the development of the disease [3] . Typical DYT1 dystonia comprises onset of dystonia in childhood with progression to the involvement of the trunk and other limbs [4] .
A 3-bp deletion ( GAG) in exon 5 of the DYT1 gene is responsible for almost all the cases of DYT1 dystonia [5] . This deletion results in the loss of a glutamic acid residue at position 302 or 303 in the C-terminal region of the corresponding protein TA. In addition, an in-frame 18-bp deletion ( 323-328) in DYT1 gene was found in a single family with myoclonus dystonia syndrome, in combination with a mutation in the SGCE (ε-sarcoglycan) gene that typically causes this syndrome [6] . The age of DYT1 dystonia onset, typically between 5 and 28 years, corresponds to a period of motor learning and synaptic plasticity in the basal ganglia [4] . Consistent with this observation, several studies suggested that primary dystonia, including DYT1 dystonia, is caused by a neurochemical (possibly dopaminergic) defect of the basal ganglia [7] . Also, an increase in the ratio of DA metabolites to DA was observed in post-mortem striatum of DYT1 patients, suggesting an increased DA turnover [8] .
TA structure, distribution and interacting/co-localizing partners
TA is 332 amino acids long and is a member of the AAA+ superfamily of ATPases, which typically form oligomeric complexes and act as chaperones that mediate conformational changes in target proteins [9] . They have many reported functions including protein folding and degradation, cytoskeleton dynamics, membrane trafficking, vesicle fusion and response to stress [10] . The predicted primary structure of TA contains an ATPase domain, which includes a nucleotide-binding domain, Walker A and Walker B motifs, and an α-helical domain, named sensor1 [11] . The sensor1 domain mediates substrate interactions and is critical for ATP hydrolysis. TA also contains another canonical AAA+ motif, sensor2, which is an α-helical subdomain located at the C-terminal of the core ATPase domain. Sensor2 has been suggested to mediate the transmission of the free energy of ATP hydrolysis by AAA+ proteins to their respective substrates [12] . The DYT1 GAG deletion lies within this sensor2 domain.
TA is mainly located within the lumen of the ER (endoplasmic reticulum) and the NE, the outer envelope of which is contiguous with the ER, suggesting a role for TA in the structure and/or function of these membranous structures [13, 14] . Within the CNS (central nervous system), TA mRNA and protein are present at higher levels in the dopaminergic neurons of the substantia nigra pars compacta, and also in the cerebral cortex, striatum, thalamus, hippocampus, cerebellum, midbrain, pons and spinal cord [15, 16] . TA expression is temporally and spatially regulated during brain development [17] and is found distributed throughout the cell bodies and processes and extends to the tips of dendrites and axons [18] . Mutant E-TA has a different localization pattern in cell culture systems, with redistribution to the NE and perinuclear membranous inclusions, where E-TA co-localizes with endogenous components of the NE including laminA/C and B, both in the perinuclear rim and membranous inclusions [19, 20] .
Information on potential functions(s) of TA also comes from previous studies of protein interactions and these are summarized in Table 2 . The potential functions of TA and pathogenic effects of E-TA are discussed in the following section.
Cellular functions of TA
Cytoskeleton and cell polarity TA plays an important role in the cytoskeletal network, via interaction with vimentin, a type III intermediate filament, important for motility, chemotaxis, adhesion, intracellular [26] signalling and neuronal shape, and nuclear movement during neurite outgrowth. Cultured fibroblasts from DYT1 patients showed an enrichment of vimentin in the NE and delayed adhesion compared with the control fibroblasts [24, 25] .
Overexpression of E-TA was shown to inhibit the neurite outgrowth in PC12 cells, suggesting that the TA mutant may interfere with vimentin-mediated cytoskeletal function [21, 24, 25] . In Caenorhabditis elegans, the TA homologue OOC-5 was found to be necessary for the control of spindle orientation and nuclear-centrosome complex rotation [27] . Further work has suggested that TA may influence the cytoskeleton, nuclear polarization and migration through its association with nesprin-3, a protein that spans the outer nuclear membrane and links with vimentin [26] . Finally, TA may affect microtubule stabilization, neurite outgrowth and polarity through the reported binding to the microtubule-associated protein, tau protein [28] .
TA in the NE
In the NE, TA may play a crucial role by its binding to specific NE proteins, such as LAP1 (lamina-associated polypeptide 1) [22] . Accumulation of E-TA is associated with abnormal morphology of the NE, including formation of blebs and herniations into the perinuclear area in cultured primary neurons from homozygous knockout and E-TA knock-in mice [29] .
Redistribution of TA in the NE was also seen by mutating the ATP hydrolysis motif, suggesting that when TA binds its substrate in an ATP-bound state in the absence of hydrolysis, it remains 'trapped' in the NE [30] Chaperone function
On the basis of the homology of AAA+ ATPases and the HSP (heat-shock protein)/Clp, a role for TA as a chaperone has been investigated. HSPs are critical factors for stress response involved in folding of proteins, prevention of aggregation, ubiquitination and degradation of misfolded proteins. TA co-localizes with the HSPs ubiquitin and α-synuclein in Lewy bodies in neurons from Parkinson's disease brains [31] . Moreover, overexpression of TA prevented the formation of α-synuclein aggregates in a cell culture model as well as polyglutamine repeat-induced protein aggregates in C. elegans [32, 33] . However, TA does not behave as a classical heat-shock chaperone, and is not found to be up-regulated in response to a variety of stresses, including ER stress [34] .
Secretory pathway
TA has been implicated in the secretory pathway processing of proteins. Overexpression of TA suppresses the delivery to the plasma membrane of polytopic membrane proteins, such as the DAT (DA transporter) [35] and mutant form of SGCE [36] . wt-TA (wild-type TA) overexpression caused the intracellular retention and degradation of these proteins, whereas E-TA lacked this effect. TA may participate in the quality control process of folding and assembly of proteins in the ER and may co-operate with the proteasome in clearance of misfolded proteins from the cell.
Further support for this can be found in a previous study that showed reduced secretion of a luciferase reporter protein in fibroblasts from DYT1 patients compared with control fibroblasts [37] . E-TA may negatively interfere with this function by sequestering some proteins from the secretory pathway into the inclusions. For instance, VMAT2 (vesicular monoamine transporter 2), a crucial regulator of DA levels, was found entrapped in membrane inclusions in SH-SY5Y cells overexpressing E-TA [38] .
SV transport and turnover and neurotransmission
Despite the fact that TA is widely expressed in human tissue, mutant E-TA gives rise to a specific neurological phenotype, suggesting that the role of TA is essential in a selected neuronal subpopulation. TA localization in neurons is different from that in non-neuronal cells lines and both the transcript and protein stain neuronal bodies and processes and extend to the tips of dendrites and axons [18, 21] . Ultrastructural studies in primate and human striatum have shown that TA immunostaining is associated with small clear vesicles within axons and presynaptic terminals, and TA is also found enriched in synaptosomal membrane fractions [18] . In SH-SY5Y neuroblastoma cells, TA was found in the cytosol and neural processes, with punctate staining patterns reminiscent of other membrane-associated proteins [25] , with partial co-localization to VAMP (vesicle-associated membrane protein)/synaptobrevin (a marker of SVs). In differentiated PC12 cells, TA was found to co-localize with snapin [SNARE (soluble N-ethylmaleimide-sensitive fusion protein-attachment protein receptor)-associated protein] on dense-core granules at the tips of cells [23] .
TA may also regulate vesicular traffic and consequently neurotransmitter turnover. In Drosophila TA interacts with the AP-3 (adaptor protein 3) complex, which is involved in the transport process from the Golgi to the lysosome [39] , SV formation and the sorting of proteins into SVs. In an SH-SY5Y neuroblastoma cell model, TA was found to interact with snapin, an important component for vesicle exocytosis, which promotes vesicle docking by enhancing the interaction between the SNARE complex and the SV marker, SytI (synaptotagmin I) [40] . Recent studies in snapindeficient mice suggest that snapin has two roles in enhancing the efficacy of SV priming and in fine-tuning synchronous SV fusion [41] .
In SH-SY5Y cells, overexpressed wt-TA negatively affects SV recycling. Conversely, overexpression of E-TA caused retention of SytI on the plasma membrane and increased exocytosis, as a probable consequence of the sequestration of snapin and TA from the synaptic compartment to the inclusions. Notably, knockdown of TA and mutant overexpression produced a similar phenotype, supporting the view that E-TA is a loss-of-function mutation [23] . It is possible that TA may act as a chaperone not only at the ER but also at the synapse, by mediating the transport, assembly and disassembly of the molecular complex and consequently affecting SV turnover and neurotransmitter release.
The study of transgenic mouse models has also provided in vivo evidence for abnormal neurotransmission. In a mouse line overexpressing mutant E-TA [42] , it was shown that there was reduced DA release compared with wild-type mice in striatal slices stimulated with amphetamine [43] . The overall striatal levels of DA and metabolites were not altered, nor were there any differences in densities of presynaptic transporters (DAT and VMAT) or postsynaptic striatal D1 or D2 receptors. These results could be explained by mutant E-TA interfering with the transport or release of DA. Electrophysiological studies in the same transgenic mice showed an altered response of cholinergic interneurons to D2 receptor activation, resulting in an excitatory effect rather than the inhibition of cholinergic activity seen in wild-type mice [44] .
E-TA dominant-negative function
AAA+ ATPases form typical homohexameric ring structures, which are essential for their ATPase activity. It is suggested that TA also forms homohexamers and that loss of the glutamic acid residue in E-TA might lead to a conformational change in the normal ring structure with consequent inhibition of TA activity in a dominant-negative manner. Re-localization of E-TA may also adversely affect cellular TA function by depleting it from sites of action, such as the NE, ER, cytoplasm or synapses. It is possible that GAG mutation may disrupt the formation of a stable oligomeric complex, leading to premature degradation [45] .
Alternatively, E-TA may bind wt-TA and act as a dominantnegative mutant by sequestering wt-TA to the NE and perinuclear inclusions. In support of this is recent work showing altered binding of E-TA to the transmembrane proteins LAP1 and LULL1 [46] .
Conclusions
Despite the widespread distribution of human TA in neuronal and non-neuronal tissue, it is remarkable that the only clinical manifestation of E-TA is dystonia due to CNS dysfunction, suggesting that TA has a neuronal cell-specific role, which is affected by expression of mutant TA. It is likely that TA, in keeping with other AAA+ proteins, acts as a chaperone, working at a number of cellular compartments by interacting with different binding partners, including the transmembrane proteins LAP1 and LULL1 in NE and ER [22, 46] , KLC1 (kinesin light chain 1) in the cytoplasm [21] , the intermediate filament vimentin [25] and snapin on dense-core granules [23] . Further, based on in vitro and in vivo studies, the possibility that E-TA leads to dysregulation of SV function and neurotransmission is a tantalizing hypothesis for the genesis of dystonic movements.
